Incomplete response to therapy in intermediate- and high-risk thyroid cancer

被引:2
|
作者
Alzahrani, Ali S. [1 ,2 ]
Mukhtar, Noha [1 ,2 ]
机构
[1] King Faisal Specialist Hosp & Res Ctr, Dept Med, Riyadh, Saudi Arabia
[2] King Faisal Specialist Hosp & Res Ctr, Dept Mol Oncol, Riyadh, Saudi Arabia
关键词
Thyroid cancer; Differentiated thyroid cancer; Risk stratification; Recurrence; DISTANT METASTASES; PROGNOSTIC VALUE; STAGING SYSTEM; PAPILLARY; CARCINOMA; AGE; SURVIVAL; RECURRENCE; CLASSIFICATION; ASSOCIATION;
D O I
10.1007/s12020-022-03187-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context The American Thyroid Association (ATA) risk stratification system predicts risk of recurrence of differentiated thyroid cancer (DTC). Although the majority of patients achieve an excellent response, patients with intermediate- or high-risk DTC are at a significant risk of developing incomplete responses. We undertook this work to understand the factors associated with development of biochemically or structurally incomplete response in these two risk subgroups of DTC. Patients and methods We retrospectively reviewed 287 consecutive patients with intermediate- (213 patients) or high-risk (74 patients) DTC. All patients underwent total thyroidectomy with (223 patients) or without (64 patients) lymph node dissection and 94% of them received at least one dose of I-131ablation/therapy. Univariate and multivariate analysis and Kaplan Meier analysis were used to compare patients who achieved an excellent response with those who continued to have biochemically or structurally incomplete responses. Results In univariate and multivariate analyses, age (P 0.002, Odds ratio 4.8, 95% CI: 1.8-12.9), tumor size (P 0.027, Odds ratio 1.30, 95% CI: 1.03-1.64) and distant metastases (P < 0.0001, Odds ratio 44.6, 95% CI: 10.7-184.5) were significantly associated with the risk of developing biochemically or structurally incomplete statuses. Patients >= 55 years, tumors > 2.5 cm and presence of distant metastasis were associated with higher risk of incomplete response and death from DTC. However, when this analysis was performed on intermediate and high-risk groups separately, only age was consistently associated with risk of biochemically or structurally incomplete response in either and both groups. Conclusion Age is a strong predictor of biochemically and structurally incomplete responses in patients with intermediate and high-risk DTC.
引用
收藏
页码:531 / 542
页数:12
相关论文
共 50 条
  • [31] Changes in Magnetic Resonance Imaging Radiomic Features in Response to Androgen Deprivation Therapy in Patients with Intermediate- and High-risk Prostate Cancer
    Tharmalingam, H.
    Tsang, Y. M.
    Alonzi, R.
    Beasley, W.
    Taylor, N. J.
    McWilliam, A.
    Padhani, A.
    Choudhury, A.
    Hoskin, P. J.
    [J]. CLINICAL ONCOLOGY, 2022, 34 (06) : E246 - E253
  • [32] Proton Beam Therapy Alone for Intermediate- or High-Risk Prostate Cancer: An Institutional Prospective Cohort Study
    Arimura, Takeshi
    Yoshiura, Takashi
    Matsukawa, Kyoo
    Kondo, Naoaki
    Kitano, Ikumi
    Ogino, Takashi
    [J]. CANCERS, 2018, 10 (04)
  • [33] Use of Androgen Deprivation Therapy With Radiotherapy for Intermediate- and High-Risk Prostate Cancer Across the United States
    Falchook, Aaron D.
    Basak, Ramsankar
    Mohiuddin, Jahan J.
    Chen, Ronald C.
    [J]. JAMA ONCOLOGY, 2016, 2 (09) : 1236 - 1238
  • [34] Optimal treatment for intermediate- and high-risk, nonmuscle-invasive bladder cancer
    van der Meijden, A. P. M.
    [J]. THESCIENTIFICWORLDJOURNAL, 2006, 6 : 2611 - 2616
  • [35] Thermal Partial Prostate Ablation for Intermediate- and High-risk Prostate Cancer: Con
    Gaffney, Christopher D.
    Ehdaie, Behfar
    [J]. EUROPEAN UROLOGY FOCUS, 2023, 9 (04): : 660 - 661
  • [36] Course and Predictive Factors of Incomplete Response to Therapy in Low- and Intermediate-Risk Thyroid Cancer
    Alzahrani, Ali S.
    Moria, Yosra
    Mukhtar, Noha
    Aljamei, Hadeel
    Mazi, Sedra
    Albalawi, Lina
    Aljomaiah, Abeer
    [J]. JOURNAL OF THE ENDOCRINE SOCIETY, 2021, 5 (01) : 1 - 10
  • [37] A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer
    Armstrong, Andrew J.
    Netto, George J.
    Rudek, Michelle A.
    Halabi, Susan
    Wood, David P.
    Creel, Patricia A.
    Mundy, Kelly
    Davis, S. Lindsay
    Wang, Ting
    Albadine, Roula
    Schultz, Luciana
    Partin, Alan W.
    Jimeno, Antonio
    Fedor, Helen
    Febbo, Phillip G.
    George, Daniel J.
    Gurganus, Robin
    De Marzo, Angelo M.
    Carducci, Michael A.
    [J]. CLINICAL CANCER RESEARCH, 2010, 16 (11) : 3057 - 3066
  • [38] Overview of Management of Intermediate- and High-Risk Pulmonary Embolism
    Tapson, Victor F.
    Weinberg, Aaron S.
    [J]. CRITICAL CARE CLINICS, 2020, 36 (03) : 449 - +
  • [39] Plasma Selenium, Manganese Superoxide Dismutase, and Intermediate- or High-Risk Prostate Cancer
    Chan, June M.
    Oh, William K.
    Xie, Wanling
    Regan, Meredith M.
    Stampfer, Meir J.
    King, Irena B.
    Abe, Miyako
    Kantoff, Philip W.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (22) : 3577 - 3583
  • [40] Development and validation of a lung metastasispredicting Nomogram for intermediate- to high-risk differentiated thyroid carcinoma patients
    Yu, F.
    Wang, J.
    Yang, W.
    Yang, Z.
    Ma, W.
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S667 - S667